Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Technical420 Site Search

Returned 3 result(s).

How Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?

Last month, Canada’s Federal Court of Appeals passed a decision from the Ministry of Health to provide a subsidiary of Johnson and Johnson (NYSE: JNJ) data protection for Spravato, a ketamine treatment that has been approved for depression. The drug is the first ketamine treatment to be approved to treat…

Field Trip Health Is Taking A Diversified Approach To Assisted Psychedelic Therapies

So far this year, we have noticed a significant increase in the amount of interest in the psychedelic therapy market and this is a trend that we are closely following. Following the completion of a few successful reverse takeovers, we have started to see a spike in the number of…

Atai Life Sciences Is Betting BIG On The Shift In Psychedelics To Treat Mental Illness

2020 has been a tough year for global markets and this is a trend that we have been closely following. During the last year, we have seen a rapid increase in the number of companies that are in the psychedelic market and this is a vertical that we have become…

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.